Sign In
Buy INDV
Indivior Earnings Calls
| Release date | Apr 30, 2026 |
| EPS estimate | $0.640 |
| EPS actual | $0.96 |
| EPS Surprise | 50.00% |
| Revenue estimate | 272.84M |
| Revenue actual | 317M |
| Revenue Surprise | 16.19% |
| Release date | Feb 26, 2026 |
| EPS estimate | $0.650 |
| EPS actual | $0.82 |
| EPS Surprise | 26.15% |
| Revenue estimate | 305.62M |
| Revenue actual | 358M |
| Revenue Surprise | 17.14% |
| Release date | Oct 30, 2025 |
| EPS estimate | $0.380 |
| EPS actual | $0.720 |
| EPS Surprise | 89.47% |
| Revenue estimate | 306.22M |
| Revenue actual | 314M |
| Revenue Surprise | 2.54% |
| Release date | Jul 31, 2025 |
| EPS estimate | $0.260 |
| EPS actual | $0.510 |
| EPS Surprise | 96.15% |
| Revenue estimate | 255.233M |
| Revenue actual | 302M |
| Revenue Surprise | 18.32% |
Last 4 Quarters for Indivior
Below you can see how INDV performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 31, 2025 |
| Price on release | $20.20 |
| EPS estimate | $0.260 |
| EPS actual | $0.510 |
| EPS surprise | 96.15% |
| Date | Price |
|---|---|
| Jul 25, 2025 | $17.14 |
| Jul 28, 2025 | $17.09 |
| Jul 29, 2025 | $17.28 |
| Jul 30, 2025 | $17.40 |
| Jul 31, 2025 | $20.20 |
| Aug 01, 2025 | $21.05 |
| Aug 04, 2025 | $21.22 |
| Aug 05, 2025 | $21.80 |
| Aug 06, 2025 | $22.00 |
| 4 days before | 17.85% |
| 4 days after | 8.91% |
| On release day | 4.21% |
| Change in period | 28.35% |
| Release date | Oct 30, 2025 |
| Price on release | $29.13 |
| EPS estimate | $0.380 |
| EPS actual | $0.720 |
| EPS surprise | 89.47% |
| Date | Price |
|---|---|
| Oct 24, 2025 | $25.13 |
| Oct 27, 2025 | $24.78 |
| Oct 28, 2025 | $24.91 |
| Oct 29, 2025 | $25.24 |
| Oct 30, 2025 | $29.13 |
| Oct 31, 2025 | $29.37 |
| Nov 03, 2025 | $31.20 |
| Nov 04, 2025 | $32.00 |
| Nov 05, 2025 | $32.05 |
| 4 days before | 15.92% |
| 4 days after | 10.02% |
| On release day | 0.82% |
| Change in period | 27.54% |
| Release date | Feb 26, 2026 |
| Price on release | $33.71 |
| EPS estimate | $0.650 |
| EPS actual | $0.82 |
| EPS surprise | 26.15% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $33.89 |
| Feb 23, 2026 | $32.93 |
| Feb 24, 2026 | $33.06 |
| Feb 25, 2026 | $33.63 |
| Feb 26, 2026 | $33.71 |
| Feb 27, 2026 | $32.72 |
| Mar 02, 2026 | $31.98 |
| Mar 03, 2026 | $30.87 |
| Mar 04, 2026 | $32.16 |
| 4 days before | -0.531% |
| 4 days after | -4.60% |
| On release day | -2.94% |
| Change in period | -5.10% |
| Release date | Apr 30, 2026 |
| Price on release | $36.78 |
| EPS estimate | $0.640 |
| EPS actual | $0.96 |
| EPS surprise | 50.00% |
| Date | Price |
|---|---|
| Apr 24, 2026 | $33.23 |
| Apr 27, 2026 | $34.31 |
| Apr 28, 2026 | $34.43 |
| Apr 29, 2026 | $34.15 |
| Apr 30, 2026 | $36.78 |
| May 01, 2026 | $37.66 |
| May 04, 2026 | $38.98 |
| May 05, 2026 | $39.59 |
| May 06, 2026 | $40.61 |
| 4 days before | 10.68% |
| 4 days after | 10.41% |
| On release day | 2.39% |
| Change in period | 22.21% |
Indivior Earnings Call Transcript Summary of Q1 2026
Indivior reported strong Q1 2026 results driven primarily by U.S. SUBLOCADE performance. Total net revenue grew 19% year-over-year to $317M and SUBLOCADE net revenue rose 32% to $232M, supported by 20% dispense unit growth and record new patient starts. Management raised full-year 2026 guidance: SUBLOCADE revenue is now expected to be $950M–$990M (midpoint +13% y/y) and adjusted EBITDA $620M–$660M (midpoint +50% y/y), implying ~51% EBITDA margin. The company executed balance sheet actions (issued $500M convertible notes, repurchased $125M of shares) and retains $275M available under its buyback program. Commercial execution highlights include the DTC “Move Forward in Recovery” campaign, improved specialty pharmacy partnerships, and focus on driving accelerated second-dose uptake. R&D pipeline reprioritization: INDV-6001 will not advance to Phase III (rights amended with Alar), and INDV-2000 failed to meet the primary endpoint in Phase II for OUD but showed an exploratory signal at 200 mg across polysubstance outcomes; Indivior will not progress INDV-2000 internally for OUD and will pursue BD opportunities. Management emphasized focus on commercial-stage business development (assets with >$200M peak sales potential), maintaining a therapeutically agnostic approach, and staying disciplined on OpEx while investing behind SUBLOCADE growth.
